Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 nov. 2020 14h57 HE | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; November 10, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,402 shares as a consequence of the exercise of employee warrants. The...
10 nov. 2020 07h59 HE | Source: Genmab A/S

Genmab to Present at Jefferies Virtual London Healthcare Conference

Media Release Copenhagen, Denmark, November 10, 2020 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. and CFO Anthony Pagano, will present an update at the Jefferies...
05 nov. 2020 08h39 HE | Source: Genmab A/S

Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Company Announcement First Phase 3 study of epcoritamab as part of broad clinical development plan with AbbVieDiffuse Large B-cell Lymphoma is the most common form of non-Hodgkin’s lymphoma worldwide...
05 nov. 2020 06h26 HE | Source: Genmab A/S

Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis

Media Release Copenhagen, Denmark, November 5, 2020 Janssen submitted a Type II variation application to the European Medicines Agency for subcutaneous formulation of daratumumab in combination...
04 nov. 2020 11h04 HE | Source: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2020

November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020HighlightsNovartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple...
04 nov. 2020 10h13 HE | Source: Genmab A/S

Genmab Announces Data to be Presented at 2020 ASH Annual Meeting

Media Release Copenhagen, Denmark, November 4, 2020 More than 40 abstracts on Genmab owned and partnered programs scheduled for presentation at ASHData from ongoing Phase I/II epcoritamab trial...
30 oct. 2020 07h15 HE | Source: Genmab A/S

Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020 ADC Therapeutics to continue the development and commercialization of CamiGenmab to receive mid-to-high single-digit...
21 oct. 2020 16h48 HE | Source: Genmab A/S

Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis

Company Announcement Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell...
15 oct. 2020 09h02 HE | Source: Genmab A/S

Genmab to Host Capital Markets Day

Media Release Copenhagen, Denmark, October 15, 2020 Genmab will host Capital Markets Day November 13, 2020Highlights to be covered will include an overview of our pipeline with focus on epcoritamab,...
14 oct. 2020 17h15 HE | Source: Genmab A/S

Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting

Media Release Copenhagen, Denmark, October 14, 2020 Preliminary data from Phase 1/2a trial of DuoBody®-PD-L1x4-1BB (GEN1046) in patients with advanced solid tumors accepted for e-poster...

Page précédente

Page suivante